Kalynn Salcedo, PA
Physician Assistant · Omaha, NENPI 1124527288
Payments from drug & device makers
Across 186 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$567
- Lilly USA, LLC$370
- Novo Nordisk$339
- Medtronic$296
- Bayer$263
- Ascensia Diabetes Care US Inc.$224
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,030100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $567 |
| Lilly USA, LLC | 24 | $370 |
| Novo Nordisk | 15 | $339 |
| Medtronic | 9 | $296 |
| Bayer | 16 | $263 |
| Ascensia Diabetes Care US Inc. | 12 | $224 |
| Sanofi-aventis U.S. LLC | 6 | $211 |
| Insulet Corporation | 5 | $165 |
| Nestle Healthcare Nutrition Inc. | 1 | $150 |
| AbbVie | 8 | $144 |
| Corcept Therapeutics | 3 | $122 |
| Dexcom, Inc. | 3 | $116 |
| Xeris Pharmaceuticals, Inc. | 6 | $106 |
| Radius Health, Inc. | 7 | $103 |
| AstraZeneca(2 entities) | 5 | $86 |
| BETA Bionics, Inc. | 7 | $86 |
| Averitas Pharma Inc. | 3 | $72 |
| Zealand Pharma US, Inc. | 3 | $69 |
| Amneal Pharmaceuticals LLC | 3 | $47 |
| Tandem Diabetes Care, Inc. | 3 | $46 |
| Boehringer Ingelheim | 3 | $44 |
| Recordati_rare_diseases_inc. | 2 | $43 |
| Soleno Therapeutics, Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $36 |
| Echosens North America, Inc. | 3 | $35 |
| Merck | 2 | $33 |
| Ascendis Pharma Endocrinology Inc | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Novartis | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $12 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,030 in reported general payments places this provider in the 90th percentile of 1,127 physician assistant providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $176,997 |
| TrulicityDulaglutide | 66 | $72,550 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $62,394 |
| MounjaroTirzepatide | 49 | $60,440 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $46,437 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $45,712 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $43,884 |
| JardianceEmpagliflozin | 44 | $41,465 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 50 | $39,431 |
| FarxigaDapagliflozin Propanediol | 26 | $22,538 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $21,655 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 23 | $20,371 |
| Humalog Kwikpen U-100Insulin Lispro | 81 | $18,772 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $18,147 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $14,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $339 | $205,858172 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $370 | $145,146160 claims |
| Boehringer IngelheimJardiance, Glyxambi | $44 | $53,83062 claims |
| AstraZenecaFarxiga | $86 | $22,53826 claims |
| AbbVieSynthroid | $144 | $3,59334 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $47 | $902148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,127 physician assistant providers in Nebraska.
Other physician assistant in Omaha
- Kimberly GatesOmaha$109K
- Kandice DoleshOmaha$106K
- Kathryn KestiOmaha$34K
- Sarah GretemanOmaha$24K
- Christopher BeasleyOmaha$15K
- Corrine GiggeeOmaha$12K
- Austin DuerksenOmaha$12K
- Erin HoffmanOmaha$12K
- Sara MasonOmaha$12K
- Sally CampbellOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.